Product Description
Cancer Molecular Diagnostics: Strategies and Trends, Market Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides 2023 to 2027
“Companion Diagnostics and Liquid Biopsy drive market growth. New cancer diagnostic segments emerging"
Publication date: July 2023
Page count: 419
After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path, with growth accelerating in all segments. A range of dynamic trends are pushing market growth and company valuations, including:
- Personalized medicine
- Pharmacogenomics
- Liquid biopsy
- Minimal residual disease testing
- Emergence of new economies with large markets
- Physician diagnostics being displaced by new intelligent diagnostic tests
Exciting technical developments especially in companion diagnostics (CDx), hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.
The report includes:
- 120+ company profiles
- Market forecasts 2023 to 2027 by cancer type
- Breast
- Colorectal
- Lung
- Prostate
- Blood
- Cervical
- Melanoma
- Companion Dx Development
- Other
- Market forecasts 2023 to 2027 by product
- MDx instruments
- MDx reagents
- MDx software and services
- Market forecasts 2023 to 2027 by place/setting
- MDx clinical laboratory
- MDx pharmaceutical
- MDx research
The report includes a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
